



Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017

December 7, 2017

SAN CARLOS, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast its Analyst Day on Wednesday, December 13, 2017 from 9:00 a.m. to 12:00 p.m. ET in New York, NY.

The event will highlight Iovance's lead clinical programs, LN-144 for the treatment of metastatic melanoma, LN-145 for recurrent and/or metastatic squamous cell carcinoma of the head and neck, and LN-145 for recurrent, metastatic or persistent cervical cancer. In addition, Iovance will discuss the expanding clinical pipeline, strategic collaborations and manufacturing plan for upcoming clinical trials.

A live webcast of the presentation can be accessed on the investor page of Iovance Biotherapeutics' website at <http://www.iovance.com>. A replay of the webcast will be archived on Iovance Biotherapeutics' website for 30 days following the presentation.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent, metastatic or persistent cervical cancer. For more information, please visit <http://www.iovance.com>.

Investor Relations Contact:

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com

Media Contact:

Evan Smith
FTI Consulting
212-850-5622
evan.smith@fticonsulting.com



Iovance Biotherapeutics, Inc.